Pyridoxamine for the Treatment of Diabetic Kidney Disease
The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
1 - 14 . (canceled)
15 . A method for treating diabetic nephropathy in a human diabetic patient comprising administering to a human diabetic patient with a baseline serum creatinine concentration of greater than or equal to 1.3 mg/dL an amount of pyridoxamine, or a pharmaceutically acceptable salt thereof, effective to slow the increase in serum creatinine levels in the human diabetic patient relative to placebo, wherein the human diabetic patient has diabetic nephropathy, macroalbuminuria, and type II diabetes.
16 - 39 . (canceled)
40 . The method of claim 15 , wherein the pyridoxamine, or a pharmaceutically acceptable salt thereof, is administered at a dose of between 25 to 1000 milligrams.
41 . The method of claim 15 , wherein the pyridoxamine, or a pharmaceutically acceptable salt thereof, is administered orally.
42 . The method of claim 40 , wherein the pyridoxamine, or a pharmaceutically acceptable salt thereof, is administered orally.
43 . The method of claim 15 , wherein the pyridoxamine, or a pharmaceutically acceptable salt thereof, is administered once or twice a day.
44 . The method of claim 40 , wherein the pyridoxamine, or a pharmaceutically acceptable salt thereof, is administered once or twice a day.
45 . The method of claim 41 , wherein the pyridoxamine, or a pharmaceutically acceptable salt thereof, is administered once or twice a day.
46 . The method of claim 42 , wherein the pyridoxamine, or a pharmaceutically acceptable salt thereof, is administered once or twice a day.